IL-3-mediated TNF production is necessary for mast cell development

Journal of Immunology

Volumn 176, Issue 4, 2006, Pages 2114-2121

  Wright, Harry V ^a   Bailey, Daniel ^a   Kashyap, Mohit ^a   Kepley, Christopher L ^a   Drutskaya, Marina S ^b   Nedospasov, Sergei A ^a,c   Ryan, John J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA; INTERLEUKIN 3; STEM CELL FACTOR; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; BONE MARROW CULTURE; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA CONTENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; MAST CELL; PERITONEUM MAST CELL; PRIORITY JOURNAL;

EID: 32044443214     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.4.2114     Document Type: Article

References (55)

1. Galli, S. J. 2000. Mast cells and husophils. Curr. Opin. Hematol. 7: 32-39.
2. Metcalfe, D. D., D. Baram, and Y. A. Mekori. 1997. Mast cells. Physiol. Rev. 77: 1033-1079.
3. Wasserman, S.I. 1990. Mast cell biology. J. Allergy Clin. Immunol. 86: 590-593.
4. Arock, M., S. N. Abraham. Z. Gao, S. Varadaradjalou, and F. Feger. 2002. The role of mast cells in host defense and their subversion by bacterial pathogens. Trends Immunol. 23: 151-158.
5. Meischer, S. M., and M. Vogel. 2002. Molecular aspects of allergy. Mol. Aspect Med. 23: 413-462.
6. Lee, D. M., D. S. Friend, M. F. Gurish, C. Benoist, D. Mathis, and M. B. Brenner. 2002. Mast cells: A cellular link between autoantibodies and inflammatory arthritis. Science 297: 1689-1692.
7. Secor, V. H., W. E. Secor, C. A. Gutekunst, and M. A. Brown. 2000. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J. Exp. Med. 191: 813-822.
8. Hara, M., K. Ono, M. W. Hwang, A. Iwasaki, M. Okada, K. Nakatani, S. Sasayama, and A. Maisumori. 2002. Evidence for a role of mast cells in the evolution to congestive heart failure. J. Exp. Med. 195: 375-38!.
9. Laine, P., A. Naukkarinen, L. Heikkila, A. Pentilla, and P. Kovanen. 2000. Adventitial mast cells connect with sensory nerve fibers in atherosclerotic coronary arteries. Circulation 101: 1665-1669.
10. Echtenacher, B., D. N. Mannel, and L. Hultner. 1996. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381: 75-77.
11. Malaviya, R., T. lkeda, E. A. Ross, and S. N. Abraham. 1996. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α. Nature 381: 77-80.
12. Ryan, J. J., and T. F. Huff. 2004. Biology of mast cells. In: Middleton's Allergy: Principles and Practice. N. F. Adkinson, ed. Mosby, St. Louis, pp. 333-346.
13. Austen, K. F., and J. A. Boyce. 2001. Mast cell lineage development and phe-notypic regulation. Lenk. Res. 25: 511-518.
14. Galli, S. J., and I. Hammel. 1994. Mast cell and basophil development. Curr. Opin. Hematol 1: 33-39.
15. Lantz, C. S., J. Boesiger, C. H. Song, N. Mach, T. Kobayashi, R. C. Mulligan, Y. Nawa, G. Dranoff, and S. J. Galli. 1998. Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature 392: 90-93.
16. Rottem, M., S. Barbieri, J. P. Kinet, and D. D. Metcalfe. 1992. Kinetics of the appearance of FcεRI-bearing cells in interleukin-3-dependent mouse bone marrow cultures: correlation with histamine content and mast cell maturation. Blood 79: 972-980.
17. Shelburne, C. P., M. E. McCoy, R. Piekorz, V. Sexl, K. H. Roh, S. M. Jacobs-Helber, S. R. Gillespie, D. P. Bailey, P. Mirmonsef, M. N. Mann, et al. 2003. Stat5 expression is critical for mast cell development and survival. Blood 102: 1290-1297.
18. Pfeffer, K. 2003. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 14: 185-191.
19. Kollias, G. 2005. TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin. Arthritis Rheum. 34(5 Suppl. 1): 3-6.
20. Feldmann, M., and R. N. Maini. 2001. Anti-TNF α therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19: 163-196.
21. Beutler, B. 2001. Autoimmunity and apoptosis: the Crohn's connection. Immunity 15: 5-14.
22. Grell, M., E. Douni, H. Wajant, M. Lohden, M. Clauss, B. Maxeiner. S. Georgopoulos, W. Lesslauer, G. Kollias, K. Pfizenmaier, et al. 1995. The transmembrane form of tumor necrosis factor is the prime activation ligand of the 80 kDa tumor necrosis factor receptor. Cell 83: 793-802.
23. Korner, H., M. Cook, D. S. Riminton, F. A. Lemckert, R. M. Hoek, B. Ledermann, F. Kontgen, B. Fazekas de St. Groth. and J. D. Sedgwick. 1997. Distinct roles for lymphotoxin-α and tumor necrosis factor in organogenesis and spatial organization of lymphoid tissue. Eur. J. Immunol. 27: 2600-2609.
24. Nuemann, B., A. Luz, K. Pfeffer, and B. Holzmann. 1996. Defective Peyer's patch organogenesis in mice lacking the 55-kD receptor for tumor necrosis factor. J. Exp. Med. 184: 259-264.
25. Pasparakis, M., L. Alexopoulou, V. Episkopou. and G. Kollias. 1996. Immune and inflammatory responses in TNFα-deficient mice: a critical requirement for TNFα in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184: 1397-1411.
26. Pfeffer, K., T. Matsuyama, T. M. Kundig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P. S. Ohashi, M. Kranke, and T. W. Mak. 1993. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73: 457-467.
27. Rothe, J., W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel,. M. Steinmetz, and H. Bluethmann. 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Lisieria monocytogenes. Nature 364: 798-802.
28. Erickson, S. L., F. J. de Sauvage. K. Kikly, K. Carver-Moore, S. Pitts-Meek, N. Gillett, K. C. Sheehan, R. D. Schreiber, D. V. Goeddel, and M. W. Moore. 1994. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372: 560-563.
29. Tile, J. P., G. Dougan, and S. N. Chatfield. 1991. The involvement of tumor necrosis factor in immunity to Salmonella infection. J. Immunol. 147: 3161-3164.
30. Takashima, K., T. Teateda, Y. Matsumoto, M. Iizawa, M. Nakao. and K. Yamagucho. 1997. Role of tumor necrosis factor α in pathogenesis of pneumococcal pneumonia in mice. Infect. Immun. 65: 257-260.
31. Witsell, A. L., and L. B. Schook. 1992. Tumor necrosis factor α is an autocrine growth regulator during macrophage differentiation. Proc. Natl. Acad. Sci. USA 89: 4754-4758.
32. Branch, D. R., and L. J. Guilbert. 1996. Autocrine regulation of macrophage proliferation by tumor necrosis factor-α. Exp. Hematol. 24: 675-681.
33. Abe, K., and S. A. Nedospasov. 2003. Distinct contributions of TNF and LT cytokines to the development of dendritic cells in vitro and their recruitment in vivo. Blood 101: 1477-1483.
34. Murase, T., T. Hotta, R. Ohno, and H. Saito. 1987. Predominant suppression of neutrophil colony growth by recombinant human tumor necrosis factor. Proc. Soc. Exp. Biol. Med. 186: 188-191.
35. Roodman, G. D., A, Bird, D. Hutzler, and W. Montgomery. 1987. Tumor necrosis factor-α and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells. Exp. Hematol 15: 928-935.
36. Furmanski, P., and C. S. Johnson. 1990. Macrophage control of normal and leukemic erythropoiesis: identification of the macrophage-derived erythroid suppressing activity as interleukin-1 and the mediator of its in vivo action as tumor necrosis factor. Blood 75: 2328-2334.
37. Jacobs-Helber, S. M., K. H. Roh, D. Bailey, E. N. Dessypris, J. J. Ryan, J. Chen, A. Wickrema, D. L. Barber, P. Dent, and S. T. Sawyer. 2003. Tumor necrosis factor-α expressed constitutively in erythroid cells or induced by erythropoictin has negative and stimulatory roles in normal erythropoiesis and erythroleukemia. Blood 101: 524-531.
38. Kuprash, D. V., A. V. Tumanov, L. J. Liepinsh, E. P. Koroleva, M. S. Drulskaya, A. A. Kruglov, A. N. Shakhov, E. Southon, M. J. Murphy, L. Tessarollo, et al. 2005. Novel tumor necrosis factor (TNF) knockout mice that lack Peyer's patches. Eur. J. Immunol. 35: 1592-1600.
39. Bailey, D. P., M. Kashyap, P. Mirmonsef, L. A. Bouton, J. Domen, J. Zhu, E. N. Dessypris, and J. J. Ryan. 2004. Interleukin-4 elicits apoptosis of developing mast cells via a Stat6-dependent mitochondrial pathway. Exp. Hematol. 32: 52-59.
40. Chan, S. L., S. P. Tammariello, S. Estus, and M. P. Mattson. 1999. Prostate apoptosis response-4 mediates lrophic factor withdrawal-induced apoplosis of hippocampal neurons: actions prior to mitochondrial dysfunction and caspase activation. J. Neurochem. 73: 502-512.
41. Bojes, H. K., X. Feng, J. P. Kehrer, and G. M. Cohen. 1999. Apoptosis in hematopoietic cells (FL5.12) caused by interleukin-3 withdrawal: relationship to caspase activity and loss of gluialhione. Cell Death Differ. 6: 61-70.
42. L. J Clin. Immunol. 21: 171-174.
43. Aggarwal, B. B. 2003. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3: 745-756.
44. Ware, C. F. 2003. Introduction. Cytokine Growth Factor Rev. 14: 181-184.
45. Azzolina, A., P. Guarnieri, and N. Lampiasi. 2002. Involvement of p38 and JNK MAPK pathways in substance P-induced production of TNF-α by peritoneal mast cells. Cytokine 18: 72-80.
46. Chayama, K., P. J. Papst, T. P. Garrington, J. C. Pratt, T. Ishizuka, S. Webb, S. Ganiatsas, L. I. Zon, W. Sun, G. L. Johnson, and E. W. Gelfand. 2001. Role of MEKK2-MEK5 in the regulation of TNF-α gene expression and MEKK2-MKK7 in the activation of c-Jun N-terminal kinase in mast cells. Proc. Natl. Acad. Sci. USA 98: 4599-4604.
47. Coward, W. R., Y. Okayama, H. Sagara, S. J. Wilson, S. T. Holgate, and M. K. Church. 2002. NF-κB and TNF-α: a positive autoerine loop in human lung mast cells? J. Immunol. 169: 5287-5293.
48. Nakamura, T., R. Ouchida, T. Kodama, T. Kawashima, Y. Makino, N. Yoshikawa, S. Watanabe, C. Morimoto, T. Kitamura, and H. Tanaka. 2002. Cytokine receptor common β subunit-mediated STAT5 activation confers NF-κB activation in murine proB cell line Ba/F3 cells. J. Biol. Chem. 277: 6254-6265.
49. Besancon, F., A. Atfi, C. Gespach, Y. E. Cayre, and M. F. Bourgeade. 1998. Evidence for a role of NF-κB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor β fusion protein. Proc. Natl. Acad. Sci. USA 95: 8081-8086.
50. - bone marrow progenitors express Fcγ-RII but do not express Fcε-RI until mast cell granule formation. J. Immunol. 154: 355-362.
51. Hu, Z., K. Kobayashi, N. Zenda, and T. Shimamura. 1997. Tumor necrosis factor-α- and interleukin 6-triggered mast cell development from mouse spleen cells. Blood 89: 526-533.
52. Kawakami, T., and S. J. Galli. 2002. Regulation of mast-cell and basophil function and survival by IgE. Nat. Rev. Immunol. 1: 773-786.
53. Odom, S., G. Gomez, M. Kovarova, Y. Furumoto, J. J. Ryan, H. V. Wright, C. Gonzȧlez-Espinosa, M. L. Hibbs, K. W. Harder, and J. Rivera. 2004. Negative regulation of immunoglobulin E-dependent allergic responses by Lyn kinase. J. Exp. Med. 199: 1491-1502.
54. Mikuls, T. R., and A. L. Weaver. 2003. Lessons learned in the use of tumor necrosis factor-α inhibitors in the treatment of rheumatoid arthritis. Curr. Rheumatol. Rep. 5: 270-277.
55. Ziolkowska, M., and W. Maslinski. 2003. Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis. Curr. Opin. Rheumatol. 15: 267-273.